# US 2016/0355608 A1 · Heterodimeric antibodies that bind cd3 and tumor antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355608 A1
- Document ID: US20160355608A1
- Status: Published application
- Kind: A1
- Application number: 15/141,350
- Filed: 2016-04-28
- Published: 2016-12-08
- Earliest claimed: 2014-11-26
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Matthew J. Bernett; Gregory Moore; John Desjarlais; Seung Chu; Rumana Rashid; Umesh Muchhal; Sung-Hyung Lee
- Web page: https://patentgrep.com/patent/US20160355608A1

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2887: {against CD20}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/3061: {Blood cells}
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/522: CH1 domain
- C07K 2317/526: CH3 domain
- C07K 2317/528: CH4 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to novel heterodimeric antibodies.

## Claims

### Claim at position 1

-50. (canceled)

### Claim 51

A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a first Fc domain;
ii) an anti-CD3 scFv comprising a scFv variable light domain, an scFv linker and a scFv variable heavy domain; wherein said scFv is covalently attached to the N-terminus of said Fc domain using a domain linker;
b) a second monomer comprising a heavy chain comprising:
i) a heavy variable domain; and
ii) a heavy chain constant domain comprising a second Fc domain; and
c) a light chain comprising a variable light domain and a variable light constant domain; wherein said anti-CD3 scFv is selected from the group consisting of anti-CD3 H1.32_L1.47 (SEQ ID NO:18), anti-CD3 H1.89_L1.47 (SEQ ID NO:27), anti-CD3 H1.90_L1.47 (SEQ ID NO:36) and anti-CD3 H1.33_L1.47 (SEQ ID NO:45), and said heavy variable domain and said light variable domain bind a TTA.

### Claim 52 (depends on 51)

A heterodimeric antibody according to claim 51 wherein said TTA is selected from the group consisting of CD19, CD20, CD38 and CD123.

### Claim at position 4

-72. (canceled)

### Claim 73 (depends on 51)

A nucleic acid composition comprising:
a) a first nucleic acid encoding said first monomer of claim 51;
b) a second nucleic acid encoding said second monomer of claim 51; and
c) a third nucleic acid encoding said light chain of claim 51.

### Claim 74 (depends on 51)

An expression vector composition comprising:
a) a first expression vector comprising a first nucleic acid encoding said first monomer of claim 51;
b) a second expression vector comprising a second nucleic acid encoding said second monomer of claim 51; and
c) a third expression vector comprising a third nucleic acid encoding said light chain of claim 51.

### Claim 75 (depends on 74)

A host cell comprising said expression vector composition of claim 74.